Clinical Trials Browser

Active not recruiting × Liver Neoplasms × pembrolizumab × Clear all

NCT05438420 2026-02-24

Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

Phase 1/2 Active not recruiting

GastrointestinalGynecologic

Uterine Cervical Neoplasms, Esophageal Neoplasms, Liver Neoplasms, Stomach Neoplasms